CD8A and neoplasm: Key in vivo endpoints will include tumor growth inhibition and tumor rechallenge studies, animal survival, and spatial distribution of ICD markers (e.g., HSP‐70, calreticulin, HMGB1) and tumor‐infiltrating CD8+ T cells with respect to V‐LNP distribution and incident light propagation in tumors.